Novel Lipid Mediators as a Promising Therapeutic Strategy for Ischemic Stroke
Medical Research Archives · 31.01.2023 · 11 (1)
DOI: 10.18103/mra.v11i1.3333 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medical Research Archives, online erschienen am 31.01.2023. Verfasst von Ludmila Belayev und 2 weiteren Autor:innen. Beteiligte Einrichtung: Neuroscience Center of Excellence, School of Medicine, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA. Die Arbeit wurde bisher 5-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS.
Themen: Schlaganfall
Abstract (Originalsprache)
Despite displaying efficacy in experimental stroke studies, neuroprotection has failed in clinical trials. The translational difficulties include a limited methodological agreement between preclinical and clinical studies and the heterogeneity of stroke in humans compared to standardized strokes in animal models. Promising neuroprotective approaches based on a deeper understanding of the complex pathophysiology of ischemic stroke, such as blocking pro-inflammatory pathways plus pro-survival mediators, are now evaluated in preclinical studies. Combinatorial therapy has become increasingly attractive in recent years as recognizing the complexity of stroke progression becomes evident. The paper aimed to test the hypothesis that blocking pro-inflammatory platelet-activating factor receptor (PAF-R) with LAU-0901 plus administering a selected docosanoid, aspirin-triggered neuroprotectin D1 (AT-NPD1), which activates cell-survival pathways after middle cerebral artery occlusion (MCAo), would lead to neurological recovery. We have demonstrated that LAU-0901 plus AT-NPD1 treatment affords high-grade neuroprotection in MCAo, equaling or exceeding that afforded by LAU-0901 or AT-NPD1 alone at considerably moderate doses, and it has a broad therapeutic window extending to 6 hours after stroke onset.
Autor:innen und Institutionen
- Neuroscience Center of Excellence, School of Medicine, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA.
ORCID-Profile: Ludmila Belayev, Nicolas G Bazan
Förderung
- NINDS NIH HHS
Zitieren
APA
Belayev, L., Reid, M. M., & Bazan, N. G. (2023). Novel Lipid Mediators as a Promising Therapeutic Strategy for Ischemic Stroke. Medical Research Archives, 11(1). https://doi.org/10.18103/mra.v11i1.3333
Vancouver
Belayev L, Reid MM, Bazan NG. Novel Lipid Mediators as a Promising Therapeutic Strategy for Ischemic Stroke. Medical Research Archives. 2023;11(1). doi:10.18103/mra.v11i1.3333
BibTeX
@article{Belayev2023,
author = {Belayev, Ludmila and Reid, Madigan M and Bazan, Nicolas G},
title = {Novel Lipid Mediators as a Promising Therapeutic Strategy for Ischemic Stroke},
journal = {Medical Research Archives},
year = {2023},
volume = {11},
number = {1},
doi = {10.18103/mra.v11i1.3333}
}
EUVIMED